Chemokines in CSF of Alzheimer's disease patients;Quimiocinas no LCR de pacientes portadores da doença de Alzheimer

Arquivos de Neuro-Psiquiatria

Volumn 69, Issue 3, 2011, Pages 455-459

  Corrêa, Jôice Dias ^a   Starling, Daniela ^a   Teixeira, Antônio Lúcio ^a   Caramelli, Paulo ^a   Silva, Tarcília Aparecida ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Chemokines; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MALE; PATHOGENESIS; PROTEIN EXPRESSION;

EID: 79960594603     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2011000400009     Document Type: Article

References (28)

1. Olson L, Humpel C. Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp Gerontol 2010;45:41-46.
2. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
3. Bermejo P, Martin-Aragon S, Benedi J, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 2008;117:198-202.
4. Galimberti D, Schoonenboom N, Scheltens P, et al. Intrathecal chemochine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2006;66:146-147.
5. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-116.
6. Schuitemaker A, Dik MG, Veerhuis R, et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol 2009;30: 1885-1889.
7. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased Tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2008;289:2094-2103.
8. Franceschi C, Valensin S, Bonafe M, et al. The network and the remodeling theories of aging, historical background and new perspectives. Exp Gerontol 2000;35:879-896.
9. Teixeira AL, Bauer ME, Nicolato R, Reis HJ, Palotás A. Cytokines and the brain: beyond immune response. In: Fedorovich SV (Ed). Signal Transduction in nervous Cells. Trivandrum, 2008:95-115.
10. Teixeira AL, Reis HJ, Coelho FM, et al. All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's beta- amyloid peptide. Biol Psychiatry 2008;64:891-895.
11. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1200-1205.
12. Baggiolini M, Dewald B, Moser B. Interleukin 8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994;55:97-179.
13. Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord 2009;28:281-287.
14. Xia MQ, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 1999;5:32-41.
15. Galimberti D, Venturelli E, Fenoglio C, et al. IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. Eur J Neurol 2007;14:3-4.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
17. Perl DP. Neuropathology of Alzheimer's disease. Mt Sinai J Med 2010;77: 32-42.
18. Ibach B, Binder H, Dragon M, et al. Cerebrospinal fluid tau and beta- amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 2006;27:1202-1211.
19. Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol 2008; 193:183-187.
20. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 1997;51:135-138.
21. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009;118:53-69.
22. Alonso AC, Iqbal IG, Barra H S, Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal Tau. Proc Natl Acad Sci U S A 1997;94: 298-303.
23. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002;59:627-629.
24. Aevarsson O, Skoog IA. Longitudinal population study of the mini-mental state examination in the very old: relation to dementia and education. Dement Geriatr Cogn Disord 2000;11:166-175.
25. Brayne C, Ince PG, Keage HA, et al. Education, the brain and dementia: neuroprotection or compensation? Brain 2010;133:2210-2216.
26. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993;43:13-20.
27. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448-460.
28. Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:69-74.